Chemosensitivity Testing in Oncology

  • Uwe Reinhold
  • Wolfgang Tilgen

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 161)

Table of contents

  1. Front Matter
    Pages I-X
  2. In Vitro Drug Testing Methods: Recent Developments

  3. Tumor Chemosensitivity Assays: Evaluation of In Vitro Results

    1. Front Matter
      Pages 71-71
    2. Federica Di Nicolantonio, Michael Neale, Zerrin Onadim, John L. Hungerford, Judith L. Kingston, Ian A. Cree
      Pages 73-80
    3. Selma Ugurel, Wolfgang Tilgen, Uwe Reinhold
      Pages 81-92
    4. Heike Helmbach, Pranav Sinha, Dirk Schadendorf
      Pages 93-110
    5. Thomas Schöndorf, Rainer Neumann, Carolin Benz, Martina Becker, Marion Riffelmann, Uwe-Jochen Göhring et al.
      Pages 111-116
  4. Clinical Relevance of Tumor-Directed Therapy

    1. Front Matter
      Pages 117-117
    2. John P. Fruehauf, David S. Alberts
      Pages 126-145
    3. M. Untch, N. Ditsch, E. Langer, C. Kurbacher, C. Crohns, G. Konecny et al.
      Pages 146-158
    4. Marko Kornmann, Hans G. Beger, Karl H. Link
      Pages 180-195
    5. G. J. L. Kaspers, A. J. P. Veerman
      Pages 196-220
    6. Christian M. Kurbacher, Ottilia M. Grecu, Ursula Stier, Tobias J. Gilster, Margit-M. Janát, Michael Untch et al.
      Pages 221-230
    7. Tetsuro Kubota, Yoshihide Otani, Toshiharu Furukawa, Hirotoshi Hasegawa, Masahiko Watanabe, Masaki Kitajima
      Pages 231-241
  5. Back Matter
    Pages 243-245

About these proceedings


Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.


breast cancer cancer cell chemotherapy clinical trial drug drug development drug resistance leukemia malignant melanoma melanoma ovarian cancer pancreatic cancer resistance tumor

Editors and affiliations

  • Uwe Reinhold
    • 1
  • Wolfgang Tilgen
    • 1
  1. 1.Hautklinik und PoliklinikUniversitätskliniken des SaarlandesHomburg/SaarGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2003
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-62412-4
  • Online ISBN 978-3-642-19022-3
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site